Aetiology | No of patients | No of patients (%) with GBV-C | No of patients out of those tested with known GBV-C seroconversion after admission | ||||||
---|---|---|---|---|---|---|---|---|---|
RNA | Antibodies | Markers | RNA | Antibodies | |||||
Unknown | 27 | 5 (19)1-150 | 3 (11) | 7 (26)1-151 | 3/4 | —1-151 | |||
Viral | 6 | 0 | 2 (33) | 2 (33) | — | — | |||
Drug related | 14 | 2 (14) | 3 (21) | 5 (36) | 1/1 | — | |||
Miscellaneous | 11 | 2 (18) | 5 (45)1-150 | 6 (55)1-164 | 0/11-164 | 2/41-164 | |||
Total | 58 | 9 (16)1-160 | 13 (22)1-150 | 20 (34) | 4/6 | 2/4 | |||
Healthy subjects | 43 | 1-170 | 2 (5) | — | — | — |
↵1-150 p<0.05 compared with the healthy subjects (Fisher’s exact test).
↵1-160 p<0.01 compared with the healthy subjects (Fisher’s exact test).
↵1-151 Patient FH5 had GBV-C E2 antibodies at admission and became positive for GBV-C RNA after treatment. The sample obtained after treatment became exhausted prior to antibody analysis.
↵1-164 Patient FH7 was positive for both GBV-C RNA and GBV-C E2 antibodies in samples obtained before and after treatment of FHF which presented 13 days after a bone marrow transplant.
↵1-170 Frequency of GBV-C RNA (3/100; 3%) in healthy Swedish subjects.21